Uji, Japan

Masahiro Okamoto

This inventor holds 1 USPTO granted patent. Top assignee: Santen Pharmaceutical Co., Ltd.. Active years: 1994.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiro Okamoto. Retrieved from https://idiyas.com/inventor/masahiro-okamoto-hfz2r2i1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1994

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masahiro Okamoto: Innovator in Bicyclic Compounds

Introduction

Masahiro Okamoto is a notable inventor based in Uji, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of bicyclic compounds. His work is aimed at addressing critical health issues, including immunodeficiency and autoimmune diseases.

Latest Patents

Masahiro Okamoto holds a patent for bicyclic compounds, specifically a compound of the formula [I]. The compounds of this invention exhibit excellent thymulin-line activities, which are expected to be beneficial in the treatment of various diseases. This innovative approach highlights his commitment to advancing medical science.

Career Highlights

Okamoto is associated with Santen Pharmaceutical Co., Ltd., a company known for its focus on ophthalmology and innovative therapies. His role in the company has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Masahiro Okamoto has collaborated with esteemed colleagues such as Shiro Mita and Yoichi Kawashima. These partnerships have fostered a collaborative environment that enhances the potential for innovative discoveries.

Conclusion

Masahiro Okamoto's work in bicyclic compounds represents a significant advancement in the treatment of critical health conditions. His contributions to Santen Pharmaceutical Co., Ltd. and collaborations with fellow researchers underscore his impact on the field of medicinal chemistry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…